Royalty Pharma PLC has undergone significant fluctuations with various stakeholders increasing or decreasing their shares. For instance,
Mitsubishi UFJ Asset Management Co. Ltd. and
OneAscent Investment Solutions LLC increased their shares, while institutions like
Deutsche Bank AG and
Vanguard Group Inc sold off part of their holdings. Notably,
Royalty Pharma's stock has repeatedly hit
52-week high marks, signaling strong investor confidence. The company further boosted its performance with a $2 billion funding deal with
Revolution Medicines and completed a significant acquisition and restructuring. On the downside, however, there were reports related to an earnings drop and the company missed Q4 revenue estimates. In terms of governance changes, Henry Fernandez resigned from the board following post-IPO growth. Other notable news included raised guidance in 2025, underlying steady growth. Furthermore,
Royalty Pharma received
positive ratings from several investment entities, along with increased price targets.
Royalty Pharma Stocks News Analytics from Wed, 04 Dec 2024 08:00:00 GMT to Sun, 17 Aug 2025 00:35:10 GMT -
Rating 7
- Innovation 1
- Information 8
- Rumor 3
